BioCentury | Jan 9, 2019
Distillery Therapeutics

Endocrine/metabolic

...Pharma Inc., Kotobuki Pharmaceutical Co. and Merck & Co. Inc. market the SGLT2 inhibitor Suglat ipragliflozin...
BioCentury | May 25, 2018
Company News

Astellas unveils new R&D strategy

...of new products and expanded labels of gastrointestinal drug Linzess linaclotide and diabetes drug Suglat ipragliflozin...
...Tokyo:4503) Tokyo, Japan Business: Other Jennie Walters CK-107, CK-2127107 Constella, Linzess, linaclotide (ASP0456, MD-1100) fezolinetant (ESN364, ESN-364) gilteritinib (ASP2215) Suglat, ipragliflozin (ASP1941) Xtandi...
BioCentury | May 22, 2018
Company News

Astellas unveils new R&D strategy

...of new products and expanded labels of gastrointestinal drug Linzess linaclotide and diabetes drug Suglat ipragliflozin...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...growing skeletons Merck & Co. Inc. (NYSE:MRK) / Astellas Pharma Inc. (Tokyo:4503) Japan approves Sujanu sitagliptin/ipragliflozin...
BioCentury | Mar 30, 2018
Clinical News

Japan approvals include Hemlibra, Shingrix Galafold

...of dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor Januvia sitagliptin and sodium-glucose cotransporter 2 (SGLT2) inhibitor Suglat ipragliflozin...
...Kisplyx (Other) Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Suglat, ipragliflozin (ASP1941) Amicus...
BioCentury | Mar 23, 2018
Company News

Japan approvals include Hemlibra, Shingrix, Galafold

...of dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor Januvia sitagliptin and sodium-glucose cotransporter 2 (SGLT2) inhibitor Suglat ipragliflozin. Chris...
...Kisplyx (Other) Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Suglat, ipragliflozin (ASP1941) Amicus...
BioCentury | Apr 28, 2014
Company News

Astellas, Kotobuki, Merck sales and marketing update

...with Kotobuki launched Suglat ipragliflozin in Japan to treat Type II diabetes. The partners said Suglat...
...2 (SGLT2) inhibitor approved for the indication in the country. Astellas will manufacture and sell Suglat...
...low-dose package and ¥205.50 ($2.01) for the high-dose package. Last year, Astellas discontinued development of ipragliflozin...
BioCentury | Jan 20, 2014
Clinical News

Suglat ipragliflozin regulatory update

...Astellas said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Suglat ipragliflozin to treat Type...
...the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat...
...Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co. , Tokyo, Japan Product: Suglat ipragliflozin ( ASP1941...
BioCentury | Jan 18, 2014
Company News

Astellas' ipragliflozin approved in Japan

...Tokyo:4503) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Suglat ipragliflozin...
...the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat...
...Merck & Co. Inc. (NYSE:MRK) will co-promote the product in Japan. Astellas discontinued development of ipragliflozin...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...Lilly and Co. , luseogliflozin in Japan from Taisho Pharmaceutical Holdings Co. Ltd. , and ipragliflozin...
Items per page:
1 - 10 of 26